Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (ILMN), a global leader in genomic sequencing technologies, provides critical tools advancing precision medicine and life science research. This dedicated news hub offers investors and industry professionals centralized access to official press releases, financial disclosures, and strategic updates directly from the company.
Track developments across key areas including quarterly earnings, sequencing platform innovations, and global health partnerships. Stay informed about regulatory milestones, product launches, and collaborations shaping the future of genomic analysis. Bookmark this page for unfiltered access to Illumina's latest announcements, enabling data-driven decisions in the rapidly evolving biotechnology sector.
Illumina (NASDAQ: ILMN) has reaffirmed its commitment to acquire GRAIL, a leader in multi-cancer early detection technology. The company is actively collaborating with the European Commission to address concerns regarding the merger. Illumina is also contesting the Commission’s jurisdiction to review the merger under EU laws. CEO Francis deSouza emphasized that the acquisition would expedite access to life-saving cancer screenings in Europe, potentially saving tens of thousands of lives and reducing healthcare costs. The deal reflects Illumina's strategy to enhance its market position in genomic health.
Illumina, Inc. (NASDAQ: ILMN) is set to release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call with CEO Francis deSouza and CFO Sam Samad will follow at 2:00 PM PT (5:00 PM ET) to discuss the financial results. Investors can access the call via the company’s website or by dialing in. A replay will be available online for 30 days post-event. As a leader in DNA sequencing and array-based technologies, Illumina focuses on enhancing human health through genomic insights.
The DNA Data Storage Alliance, created by Twist Bioscience (TWST), Illumina (ILMN), and Western Digital (WDC), has published a white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” This document discusses DNA storage's potential to address the exponential growth of digital data, highlighting that humans generated over 400 ZB of data in 2020. The paper outlines DNA's unprecedented storage density, stability, and sustainability compared to existing technologies. The Alliance aims to develop standards for interoperability in DNA storage solutions as the technology evolves.
Illumina (NASDAQ:ILMN) has partnered with Belgian Genetic Centers to assess whole-genome sequencing (WGS) for diagnosing patients with intellectual disabilities (ID) and developmental disorders (DD). The BeSolveRD study will recruit 800 pediatric patients and evaluate the economic impact of WGS versus existing care standards. Illumina will supply sequencing reagents, with the aim of influencing reimbursement decisions for WGS in routine clinical use. The study highlights WGS’s ability to identify genetic causes in rare developmental disorders.
Illumina (NASDAQ: ILMN) announced its executives will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. A fireside chat is scheduled for 7:30 am PT / 10:30 am ET. The event will be accessible via a live webcast on Illumina's website, with a replay available for at least 30 days post-event. Illumina is a leader in DNA sequencing and array-based technologies, focusing on improving human health through genomic innovation.
Illumina (NASDAQ: ILMN) announced the appointments of Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer. Susan, with over 25 years in leadership and a history of successful product development at Illumina, aims to enhance global customer relationships. Alex has extensive experience in genomics innovation and will drive research and product development. CEO Francis deSouza praised their capabilities to accelerate innovation and expand market presence, framing these leadership changes as pivotal for future growth.
Illumina executives will participate in the Bank of America 2021 Healthcare Conference on May 13, 2021. The fireside chat is scheduled for 11:45 am PT / 2:45 pm ET. Investors can access the live webcast via the Investor Info section of Illumina's website. Recordings will be available for at least 30 days post-event. Illumina continues to be a leader in DNA sequencing and array-based technologies, supporting advancements in life sciences, oncology, reproductive health, and agriculture.
Illumina (NASDAQ: ILMN) has filed a request with the General Court of the European Union to annul the European Commission's jurisdiction decision regarding its acquisition of GRAIL. This review was initiated by the Commission on April 19, 2021, seven months post-announcement. Illumina's General Counsel criticized this decision as unprecedented, asserting it could hinder innovation and inflate healthcare costs by delaying access to GRAIL's testing solutions. The company aims to resolve the review quickly while continuing to engage with the Commission.
Illumina reported a strong first quarter of 2021, achieving record revenue of $1,093 million, a 27% increase year-over-year. GAAP net income was $147 million or $1.00 per diluted share, down from $173 million or $1.17 per diluted share in the previous year. Non-GAAP net income was $278 million or $1.89 per diluted share, up from $243 million or $1.64 per diluted share. The company projects 2021 revenue growth of 25% to 28% and GAAP EPS guidance of $4.72 to $4.97. Gross margin decreased to 69.9% from 72.1% last year, while R&D and SG&A expenses rose significantly.
